Biological and molecular properties of a new αvβ 3/αvβ5 integrin antagonist

Molecular Cancer Therapeutics

Volumn 4, Issue 11, 2005, Pages 1670-1680

  Belvisi, Laura ^a   Riccioni, Teresa ^c   Marcellini, Marcella ^c   Vesci, Loredana ^c   Chiarucci, Ilaria ^c   Efrati, Daniela ^c   Potenza, Donatella ^a   Scolastico, Carlo ^a   Manzoni, Leonardo ^b   Lombardo, Katia ^c   Stasi, M Antonietta ^c   Orlandi, Augusto ^d   Ciucci, Alessandro ^d   Nico, Beatrice ^e   Ribatti, Domenico ^e   Giannini, Giuseppe ^c   Presta, Marco ^f   Carminati, Paolo ^c   Pisano, Claudio ^c  

^a UNIVERSITY OF MILAN   (Italy)

^b CNR   (Italy)

^c Sigma Tau SpA   (Italy)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

^e UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^f UNIVERSITY OF BRESCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CILENGITIDE; FIBROBLAST GROWTH FACTOR 2; PEPTIDE LIBRARY; ST 1642; ST 1643; ST 1644; ST 1646; ST 1874; ST 1934; UNCLASSIFIED DRUG; VASCULOTROPIN; VITRONECTIN RECEPTOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; BINDING ASSAY; BREAST CARCINOMA; COMPUTER ANALYSIS; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; DRUG SPECIFICITY; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MONTE CARLO METHOD; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; OSMOTIC PUMP; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN PROTEIN INTERACTION; STOCHASTIC MODEL; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; ARGININE; ASPARTIC ACID; CATTLE; CELL ADHESION; CELL LINE, TUMOR; CELL PROLIFERATION; CHICKENS; CRYSTALLOGRAPHY, X-RAY; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; FIBROBLAST GROWTH FACTOR 2; GLYCINE; GUINEA PIGS; HUMANS; INHIBITORY CONCENTRATION 50; INTEGRIN ALPHAVBETA3; INTEGRINS; LIGANDS; MICE; MICE, NUDE; MICROCIRCULATION; MODELS, CHEMICAL; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MONTE CARLO METHOD; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; OLIGOPEPTIDES; PEPTIDES, CYCLIC; PLATELET AGGREGATION; PROTEIN BINDING; PROTEIN CONFORMATION; RECEPTORS, VITRONECTIN; RECOMBINANT PROTEINS; STOCHASTIC PROCESSES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITRONECTIN;

EID: 28044458526     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-05-0120     Document Type: Article

References (62)

1. Eliceiri BP, Cheresh DA. Adhesion events in angiogenesis. Curr Opin Cell Biol 2001;13:563-8.
2. Chang C, Werb Z. The many faces of metallo proteases: cell growth, invasion, angiogenesis and metastasis. Trends Cell Biol 2001;11:S37-43.
3. Jin H, Varner J. Integrins: roles in cancer development and as treatment targets. Br J Cancer 2004;90:561-5.
4. Folkman J. Fundamental concepts of the angiogenic process. Curr Mol Med 2003;3:643-51.
5. Ruoslahti E. RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol 1996;12:697-715.
6. Aplin AE, Howe A, Alahari SK, et al. Signal transduction and signal modulation by cell adhesion receptors: the role of integrins, cadherins, immunoglobulin-cell adhesion molecules, and selectins. Pharmacol Rev 1998;50:197-263.
7. Schwartz MA, Shattil SJ. Signaling networks linking integrins and rho family GTPases. Trends Biochem Sci 2000;25:388-91.
8. Howe A, Aplin AE, Alahari SK, et al. Integrin signaling and cell growth control. Curr Opin Cell Biol 1998;10:220-31.
9. Meredith JE, Jr., Fazeli B, Schwartz MA. The extracellular matrix as a cell survival factor. Mol Biol Cell 1993;4:953-61.
10. 3 during angiogenesis. J Clin Invest 1996;98:426-33.
11. 3 for angiogenesis. Science 1994;264:569-71.
12. 5 in ocular neovascular diseases. Proc Nat Acad Sci U S A 1995;93:9764-9.
13. 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994; 79:1157-64.
14. v integrins. Science 1995;270:1500-2.
15. 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 1995;96:1815-22.
16. Borges E, Jan Y, Ruoslahti E. Platelet-derived growth factor receptor β and vascular endothelial growth factor receptor 2 bind to the β3 integrin through its extracellular domain. J Biol Chem 2000; 275:39867-73.
17. Harden I, Weiss L, Hershkoviz R, et al. Inhibition of metastatic cell colonization in murine lungs and tumor-induced morbidity by non-peptidic Arg-Gly-Asp mimetics. Int J Cancer 1993;55:1023-8.
18. 5 integrin receptor antagonist. Cancer Res 2001;61:2232-8.
19. 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994; 79:1157-64.
20. 3 during angiogenesis. J Clin Invest 1996;98:426-33.
21. Buckley CD, Pilling D, Henriquez NV, et al. RGD peptides induce apoptosis by direct caspase-3 activation. Nature 1999;397:534-9.
22. v integrins. Int J Cancer 2000;87: 716-23.
23. MacDonald TJ, Taga T, Shimada H, et al. Preferential susceptibility of brain tumors to the antiangiogenic effects of an α(v) integrin antagonist. Neurosurgery 2001;48:151-7.
24. Belvisi L, Bernardi A, Checchia A, et al. Potent integrin antagonists from a small library of RGD-including cyclic pseudopeptides. Org Lett 2001;3:1001-4.
25. Dechantsreiter MA, Flanker E, Matha B, et al. N-methylated cyclic RGD peptides as highly active and selective α(V)β(3) integrin antagonists. J Med Chem 1999;42:3033-40.
26. 3 in complex with an Arg-Gly-Asp ligand. Science 2002;296:151-5.
27. Folkman J, Haudenschild CC, Zetter BR. Long-term culture of capillary endothelial cells. Proc Natl Acad Sci U S A 1979;76:5217-21.
28. 3 receptor. J Pharmacol Exp Ther 1997; 283:843-53.
29. 3. Chem Pharm Bull (Tokyo) 2001;49:1420-32.
30. Born GVR. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962;194:927-9.
31. Ribatti D, Gualandris A, Bastaki M, et al. New model for the study of angiogenesis and antiangiogenesis in the chick embryo chorioallantoic membrane: the gelatin sponge/chorioallantoic membrane assay. J Vasc Res 1997;34:455-63.
32. Funahashi Y, Wakabayashi T, Semba T, et al. Establishment of a quantitative mouse dorsal air sac model and its application to evaluate a new angiogenesis inhibitor. Oncol Res 1999;11:319-29.
33. Chang G, Guide WC, Still WC. An internal-coordinate Monte Carlo method for searching conformational space. J Am Chem Soc 1989;111: 4379-86.
34. Guarnieri F, Still WC. A rapidly convergent simulation method: mixed Monte Carlo/Stochastic Dynamics. J Comput Chem 1994;15:1302-10.
35. Mohamadi F, Richards NGJ, Guide WC, et al. MacroModel - an integrated software system for modeling organic and bioorganic molecules using molecular mechanics. J Comput Chem 1990;11:440-67.
36. Weiner SJ, Kollman PA, Nguyen DT, et al. An all atom force field for simulations of proteins and nucleic acids. J Comput Chem 1986;7:230-52.
37. Still WC, Tempczyk A, Hawley RC, et al. Semianalytical treatment of solvation for molecular mechanics and dynamics. J Am Chem Soc 1990; 112:6127-9.
38. 3 antagonists. J Am Chem Soc 1996;118:7461-72.
39. 3 in complex with an Arg-Gly-Asp ligand. Science 2002;296:151-5.
40. Arnaout MA, Goodman SL, Xiong JP. Coming to grips with integrin binding to ligands. Curr Opin Cell Biol 2002;14:641-51.
41. Witkowski CM, Rabinovitz I, Nagle RB, Affinito KS, Cress AE. Characterization of integrin subunits, cellular adhesion and tumorigenicity of four human prostate cell lines. J Cancer Res Clin Oncol 1993;119: 637-44.
42. 3 integrin agents. J Neurooncol 2000;46:135-44.
43. 3 integrins in human melanoma growth and survival. Int J Cancer 2002; 101:156-67.
44. v Integrin expression is a novel marker of poor prognosis in advanced-stage ovarian carcinoma. Clin Cancer Res 2001;7:4073-9.
45. 3 expression confers on tumor cells a greater propensity to metastasize to bone. FASEB J 2002;16:1266-8.
46. 3 integrin receptors in breast tumor. J Exp Clin Cancer Res 2001;20:585-90.
47. Gottschalk KE, Kessler H. The structures of integrins and integrin-ligand complexes: implications for drug design and signal transduction. Angew Chem Int Ed Engl 2002;41:3767-74.
48. Belvisi L, Caporale A, Colombo M, et al. Cyclic RGD peptides containing azabicycloalkane reverse-turn mimics. Helv Chim Acta 2002; 85:4353-68.
49. Giancotti FG, Ruoslahti E. Integrin signaling. Science 1999;285: 1028-32.
50. Brakebusch C, Bouvard D, Stanchi F, et al. Integrins in invasive growth. J Clin Invest 2002;109:999-1006.
51. Giese A, Westphal M. Glioma invasion in the central nervous system. Neurosurgery 1996;39:235-52.
52. 3 integrins in melanoma cell adhesion to activated platelets under flow. J Biol Chem 1996;271:5892-900.
53. Hofmann UB, Westphal JR, Zandman AJ, et al. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression. J Pathol 2000;191:245-56.
54. Hofmann UB, Westphal JR, Van Kraats AA, et al. Expression of integrin α(v)β(3) correlates with activation of membrane-type matrix metalloproteinase-1 (MT1-MMP) and matrix metalloproteinase-2 (MMP-2) in human melanoma cells in vitro and in vivo. Int J Cancer 2000; 87:12-9.
55. Nip J, Rabbani SA, Shibata HR, et al. Coordinated expression of the vitronectin receptor and the urokinase-type plasminogen activator receptor in metastatic melanoma cells. J Clin Invest 1995;95:2096-103.
56. Burke PA, De Nardo SJ, Miers LA, et al. Cilengitide targeting of α(v)β(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Cancer Res 2002; 62:4263-72.
57. 5 in patients with advanced solid tumours. Eur J Cancer 2003;39:917-26.
58. Smith JW. Cilengitide Merck. Curr Opin Investig Drugs 2003;4: 741-5.
59. 3) antibody in patients with metastatic cancer. Cancer Biother Radiopharm 2001;16:125-32.
60. 3 inhibits Leydig cell tumor growth and the development of hypercalcemia of malignancy. Cancer Res 1998;58:1930-5.
61. 3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice. Cancer Res 2003;63:2079-87.
62. 1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice. Int J Cancer 2003;104:496-503.